AIMS: We sought to evaluate associations between baseline sphericity index (SI) and clinical outcome, and changes in SI after coronary artery bypass graft (CABG) surgery with or without surgical ventricular reconstruction (SVR) in ischaemic cardiomyopathy patients enrolled in the SVR study (Hypothesis 2) of the Surgical Treatment for Ischemic Heart Failure (STICH) trial. METHODS AND RESULTS: Among 1000 patients in the STICH SVR study, we evaluated 546 patients (255 randomized toCABG alone and 291 to CABG + SVR) whose baseline SI values were available. SI was not significantly different between treatment groups at baseline. After 4 months, SI had increased in the CABG + SVR group, but was unchanged in the CABG alone group (0.69 ± 0.10 to 0.77 ± 0.12 vs. 0.67 ± 0.07 to 0.66 ± 0.09, respectively; P < 0.001). SI did not significantly change from 4 months to 2 years in either group. Although LV end-systolic volume and EF improved significantly more in the CABG + SVR group compared with CABG alone, the severity of mitral regurgitation significantly improved only in the CABG alone group, and the estimated LV filling pressure (E/A ratio) increased only in the CABG + SVR group. Higher baseline SI was associated with worse survival after surgery (hazard ratio 1.21, 95% confidence interval 1.02 - 1.43; P = 0.026). Survival was not significantly different by treatment strategy. CONCLUSION: Although SVR was designed to improve LV geometry, SI worsened after SVR despite improved LVEF and smaller LV volume. Survival was significantly better in patients with lower SI regardless of treatment strategy.
RCT Entities:
AIMS: We sought to evaluate associations between baseline sphericity index (SI) and clinical outcome, and changes in SI after coronary artery bypass graft (CABG) surgery with or without surgical ventricular reconstruction (SVR) in ischaemic cardiomyopathypatients enrolled in the SVR study (Hypothesis 2) of the Surgical Treatment for Ischemic Heart Failure (STICH) trial. METHODS AND RESULTS: Among 1000 patients in the STICH SVR study, we evaluated 546 patients (255 randomized to CABG alone and 291 to CABG + SVR) whose baseline SI values were available. SI was not significantly different between treatment groups at baseline. After 4 months, SI had increased in the CABG + SVR group, but was unchanged in the CABG alone group (0.69 ± 0.10 to 0.77 ± 0.12 vs. 0.67 ± 0.07 to 0.66 ± 0.09, respectively; P < 0.001). SI did not significantly change from 4 months to 2 years in either group. Although LV end-systolic volume and EF improved significantly more in the CABG + SVR group compared with CABG alone, the severity of mitral regurgitation significantly improved only in the CABG alone group, and the estimated LV filling pressure (E/A ratio) increased only in the CABG + SVR group. Higher baseline SI was associated with worse survival after surgery (hazard ratio 1.21, 95% confidence interval 1.02 - 1.43; P = 0.026). Survival was not significantly different by treatment strategy. CONCLUSION: Although SVR was designed to improve LV geometry, SI worsened after SVR despite improved LVEF and smaller LV volume. Survival was significantly better in patients with lower SI regardless of treatment strategy.
Authors: A F van den Heuvel; D J van Veldhuisen; E E van der Wall; P K Blanksma; H M Siebelink; W M Vaalburg; W H van Gilst; H J Crijns Journal: J Am Coll Cardiol Date: 2000-01 Impact factor: 24.094
Authors: Roberto M Lang; Michelle Bierig; Richard B Devereux; Frank A Flachskampf; Elyse Foster; Patricia A Pellikka; Michael H Picard; Mary J Roman; James Seward; Jack S Shanewise; Scott D Solomon; Kirk T Spencer; Martin St John Sutton; William J Stewart Journal: J Am Soc Echocardiogr Date: 2005-12 Impact factor: 5.251
Authors: Jae K Oh; Eric J Velazquez; Lorenzo Menicanti; Gerald M Pohost; Robert O Bonow; Grace Lin; Anne S Hellkamp; Paolo Ferrazzi; Stanislaw Wos; Vivek Rao; Daniel Berman; Andrzej Bochenek; Alexander Cherniavsky; Jan Rogowski; Jean L Rouleau; Kerry L Lee Journal: Eur Heart J Date: 2012-05-14 Impact factor: 29.983
Authors: Eric J Velazquez; Kerry L Lee; Christopher M O'Connor; Jae K Oh; Robert O Bonow; Gerald M Pohost; Arthur M Feldman; Daniel B Mark; Julio A Panza; George Sopko; Jean L Rouleau; Robert H Jones Journal: J Thorac Cardiovasc Surg Date: 2007-12 Impact factor: 5.209
Authors: Constantine L Athanasuleas; Gerald D Buckberg; Alfred W H Stanley; William Siler; Vincent Dor; Marisa Di Donato; Lorenzo Menicanti; Sergio Almeida de Oliveira; Friedhelm Beyersdorf; Irving L Kron; Hisayoshi Suma; Nicholas T Kouchoukos; Wistar Moore; Patrick M McCarthy; Mehmet C Oz; Francis Fontan; Meredith L Scott; Kevin A Accola Journal: J Am Coll Cardiol Date: 2004-10-06 Impact factor: 24.094
Authors: Selwyn P Wong; John K French; Anna-Maria Lydon; Samuel O M Manda; Wanzhen Gao; Noel G Ashton; Harvey D White Journal: Am J Cardiol Date: 2004-11-15 Impact factor: 2.778
Authors: Michael Y C Tsang; Lilin She; Fletcher A Miller; Jin-Oh Choi; Robert E Michler; Paul A Grayburn; Robert O Bonow; Lorenzo Menicanti; Marek A Deja; Serenella Castelvecchio; Vivek Rao; Peter K Smith; Tomasz Kukulski; George Sopko; David L Prior; Eric J Velazquez; Kerry L Lee; Jae K Oh Journal: Struct Heart Date: 2019-05-23
Authors: G Pilla; M Levack; J Mcgarvey; E Hwuang; G Zsido; J Gorman; J Pilla; W R Witschey; R Gorman Journal: Cardiovasc Eng Technol Date: 2021-08-31 Impact factor: 2.495
Authors: Natalia Solowjowa; Olena Nemchyna; Yuriy Hrytsyna; Alexander Meyer; Felix Hennig; Volkmar Falk; Christoph Knosalla Journal: Front Cardiovasc Med Date: 2022-03-28
Authors: Kyung-Hee Kim; Lilin She; Kerry L Lee; Rafal Dabrowski; Paul A Grayburn; Miroslaw Rajda; David L Prior; Patrice Desvigne-Nickens; William A Zoghbi; Michele Senni; Guglielmo Stefanelli; Cesare Beghi; Thao Huynh; Eric J Velazquez; Jae K Oh; Grace Lin Journal: Cardiovasc Ultrasound Date: 2020-05-28 Impact factor: 2.062